Frailty and comorbidity in predicting community COVID-19 mortality in the UK

Biobank: the effect of sampling

Jonathan K. L. Mak[1]*, Ralf Kuja-Halkola[1], Yunzhang Wang[1], Sara Hägg[1], Juulia Jylhävä[1]

[1] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,

Sweden

*Corresponding author

Jonathan K. L. Mak

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A,

171 65 Stockholm, Sweden

Email: jonathan.mak@ki.se

Word count: Abstract: 244; Main text: 3164

Abstract

Frailty has been linked to an increased risk of coronavirus disease 2019 (COVID-19)-associated

mortality, but evidence has been inconclusive and limited to hospitalized older individuals.

Using data from the UK Biobank, we assessed whether frailty and comorbidity predict COVID-

19 mortality in the overall community population (n=437,555) and in a selected COVID-19

positive sample (n=2,059). Frailty was assessed using the Rockwood Frailty Index (FI) and the

Hospital Frailty Risk Score (HFRS), whereas comorbidity was assessed by the Charlson

Comorbidity Index (CCI). Overall, 408 individuals died of COVID-19, as ascertained from the

death register data. In the full sample, HFRS (odds ratio [OR] 1.07; 95% confidence interval [CI]

1.06–1.07) and CCI (OR 1.14; 95% CI 1.08–1.20) were associated with increased risk of COVID-

19 mortality, while FI was not statistically significantly different from null in the multivariable

logistic regression model. Adding HFRS or CCI to a model with only age and sex resulted in

significantly larger areas under the receiver operating characteristic curves. Nevertheless,

when restricting the analyses to COVID-19 positive cases, which is a sample with over-

representation of frail individuals, neither of the frailty measures or CCI added meaningful

predictive accuracy on top of age and sex. Besides, we observed stronger associations

between HFRS categories and COVID-19 mortality in relatively younger (<75 years) than older

individuals (≥75 years). Our results suggest that HFRS and CCI, which could be readily derived

from medical records, may be useful for COVID-19 mortality risk stratification in the

community.

Keywords: COVID-19, mortality, frailty, comorbidity, ageing

Introduction

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic, affecting more than 41 million individuals and causing ~1.1 million deaths worldwide as of 22nd October 2020 [1]. Accumulating evidence has shown that older age, male sex, comorbidities (e.g. diabetes, hypertension), social deprivation, black ethnicity, and laboratory indicators such as elevated levels of d-dimer and interleukin 6 are risk factors for mortality associated with COVID-19 [2–6]. However, there are relatively few data available for risk stratification in community samples compared to hospitalized patients.

Frailty, characterized as a state of increased vulnerability due to cumulative decline in multiple physiological systems [7], has consistently shown to be a strong predictor of mortality in the general population [8–10]. Various tools have been developed for measuring frailty. Some of which require assessment by physicians, such as the Clinical Frailty Scale (CFS) [11], which is more suitable in clinical settings. Another widely used measure is the Rockwood frailty index (FI), which is defined as a ratio of accumulated deficits over the total number of deficits considered [12]. The Hospital Frailty Risk Score (HFRS), constructed based on *the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision* (ICD-10) coding system [13], was developed for frailty risk stratification among older hospitalized patients and has been validated for its ability to predict adverse outcomes in various settings [14,15].

A growing number of studies have investigated the association between frailty, frequently measured using the CFS in hospital settings, and mortality among COVID-19 patients, but findings remain inconclusive. While there is evidence that frailty may add to the risk prediction in hospitalized patients [16–19], some studies have observed weak [20,21], or

even null associations [22]. Heterogeneity in the prior results may partly be owing to the

COVID-19 patients being a non-random, selected sample with a particularly high prevalence

of frailty [23], potentially causing selection bias [24]. With the continuing spread of the SARS-

CoV-2 across the world, it is of importance to assess whether COVID-19 mortality can be

predicted using other frailty and comorbidity measures, such as the HFRS and CCI that can be

readily derived from medical records, in community samples.

Using a large population cohort from the UK Biobank study, we aimed to investigate

the predictive ability of frailty, measured using the HFRS and FI, and the Charlson Comorbidity

Index (CCI) as a measure of comorbidity, for COVID-19 mortality among (a) the overall

community population and (b) COVID-19 positive individuals. Our goal was to assess whether

an easily accessible frailty and/or comorbidity measure could aid in COVID-19 mortality risk

stratification in community settings. In keeping with the observations that higher levels frailty

carry a relatively greater risk of all-cause mortality in younger than older ages [9,10,25], we

additionally assessed whether the same holds true for COVID-19 mortality. As excess mortality

due to COVID-19 may be more pronounced in younger and fitter individuals compared to old

and frail [22], it is essential to identify the factors contributing to this risk.

Methods

Study population

This is a population-based cohort study using data from the UK Biobank. Between 2006 and

2010, more than 500,000 participants completed a touch-screen questionnaire, had physical

measurements taken, and provided biological samples at one of the 22 assessment centres in

England, Wales or Scotland [26]. The UK Biobank study was approved by the North West Multi-

Centre Research Ethics Committee. All participants provided written informed consent for

data collection, analysis, and record linkage.

We excluded participants who died before 1st March 2020, requested to withdraw

from the study prior to August 2020, and had missing data on frailty and comorbidity measures.

This resulted in a sample size of n=437,555, which we referred to as the "full sample". The

subgroup of "COVID-19 positive sample" (n=2,059) consisted of those being tested positive,

diagnosed as COVID-19 patients in hospitals, and/or died of COVID-19. Analyses were

performed in both samples (**Fig. 1**).

COVID-19 diagnosis and mortality

Information on COVID-19 was obtained from three data sources linked to UK Biobank:

laboratory test results, inpatient medical records, and death register. SARS-CoV-2 PCR test

results were provided by Public Health England [27], with data available in England only,

between 16th March and 24th August 2020. Hospital inpatient data were sourced from the

Hospital Episode Statistics (HES), containing electronic medical records (i.e., ICD-10 diagnostic

codes) for all hospital admissions to National Health Service (NHS) hospitals in England up to

30th June 2020. Death register data included all deaths up until 24th August 2020 in England,

Wales and Scotland, containing ICD-10 codes assigned as individuals' primary and contributory

causes of death.

Participants were considered "COVID-19 positive" when meeting at least one of the

following criteria: (i) being positive in at least one of the PCR tests; (ii) shown as COVID-19

inpatients, with ICD-10 code U07 in hospital admission; and (iii) died of COVID-19, defined as

those with COVID-19 (ICD-10 code U07) as the primary or contributory causes of death.

COVID-19 mortality was used as the main outcome in the analyses.

Among the COVID-19 positive individuals, we compared characteristics of those

diagnosed as patients (i.e., with positive test result or was a COVID-19 inpatient; *n*=1,970) and

those died of COVID-19 but without positive test record (*n*=89), and found that both groups

were generally comparable except that individuals in the latter group were more likely to be

older, with lower income and with higher HFRS (***Appendix* Table S1**).

Frailty and comorbidity measures

Frailty was assessed using the FI and HFRS, and comorbidity was measured using the CCI

(timeline of data collection is shown in ***Appendix* Fig. S1**). The FI has previously been created

and validated by us for the UK Biobank participants, using 49 self-reported frailty items

assessed at baseline during 2006–2010 that cover a wide range of items for physical and

mental well-being (***Appendix* Table S2**) [10]. The FI was calculated as the sum of the items

(deficits) present in an individual divided by the total number of deficits, for instance, an

individual with 7 deficits from 49 items would receive an FI of 7/49=0.14. The FI was used as

both continuous and categorical variable, the latter being categorized into four groups:

relatively fit (≤0.03), less fit (>0.03–0.1), least fit (>0.1–0.21) and frail (>0.21) [28]. HFRS and

CCI were computed based on the ICD-10 codes from hospital records [13,29]. Only medical

records before 1st March 2020 were included so that diagnoses due to or associated with

COVID-19 would not bias the results. The HFRS was derived based on 109 frailty-related ICD-

10 codes, as previously described by Gibert *et al* (***Appendix* Table S3**) [13]. While it was

originally developed for older individuals (≥75 years) who had been admitted to hospital

during the prior 2 years, we utilized all available ICD-10 codes for each individual for

calculation. Each of the 109 codes were assigned a weight ranging from 0.1 to 7.1, depending

on its strength of association with frailty. HFRS was then calculated by summing all the

weighted codes, and used both as continuous and categorical measures, the latter being

categorized into low (<5), intermediate (5–15) and high (>15) risk of frailty [13]. Similarly, CCI

was derived by summing weighted ICD-10 codes, based on 17 comorbidities with weights from

1 to 6 depending on disease severity and mortality risk (*Appendix* **Table S4**) [29], and was

treated as a continuous variable in all analyses. Individuals who had missing hospital data were

those who had not been hospitalized or resided outside England (these data were only

available for England). To maximize data utilization, we first excluded individuals who

attended baseline assessment in Wales or Scotland and with missing hospital data, and then

coded the remaining individuals with missing hospital data as 0 for HFRS and CCI. As a

sensitivity analysis, we assessed whether including diagnoses from long ago would affect the

results by calculating 2-year HFRS and CCI scores using diagnoses assigned only during the past

two years (i.e., between 1st March 2018 and 29th February 2020). The FI, HFRS and CCI

correlated moderately with each other (*Appendix* **Table S5**).

Other study variables

Demographic characteristics (e.g. birth year, sex, ethnicity, smoking status) and

socioeconomic indicators (e.g. education, income, Townsend deprivation index) were

collected at baseline during 2006–2010. Education was assessed by the highest self-reported

qualification and categorized into low (no relevant qualifications), intermediate (A levels, O

levels/GCSEs, CSEs, NVQ/HND/HNC, other professional qualifications) and high (college or

university degree). Annual household income was self-reported and categorized into four

groups (<£18,000, £18,000–30,999, £31,000–51,999, ≥£52,000). Townsend deprivation index

was derived from national census data regarding unemployment, car ownership, home

ownership, and household overcrowding; higher scores correspond to higher level of

socioeconomic deprivation.

Statistical analyses

Descriptive statistics were calculated for the full sample and COVID-19 positive sample. Due

to the apparent over-representation of frail individuals in the COVID-19 positive sample, we

performed logistic regression to formally ascertain if frailty and comorbidity were

determinants for being COVID-19 positive.

In both samples, multivariable logistic regression models were applied to investigate

the associations of frailty and comorbidity (FI, HFRS, CCI, as continuous measures) with COVID-

19 mortality, adjusted for age (as linear effect, after confirming that the age-mortality

relationship was approximately linear) and sex. Ethnicity, smoking status, and socioeconomic

variables were subsequently added into the models to test whether they had an effect on the

associations. Areas under the receiver operating characteristic curves (AUROC) were used to

assess the predictiveness of the different measures. Because the HFRS was originally designed

for individuals older than 75 years and previous studies have reported age-varying risks for

frailty [9,10,25], we additionally stratified the analysis by age <75 and ≥75 years, as well as

performed an analysis with an interaction term between HFRS (continuous) and age group.

We further performed a series of sensitivity analyses to assess the robustness of our

findings, which included (i) using categorical instead of continuous FI and HFRS variables; (ii)

using 2-year HFRS and CCI, constructed by ICD-10 codes from the past 2 years only; and (iii)

performing multinomial logistic regression models to account for non-COVID-19 deaths as

competing risk, where mortality due to COVID-19 or other causes than COVID-19 were

compared to those who were alive as of 24 August 2020.

To account for multiple comparisons, the Benjamini-Hochberg false discovery rate

method was applied [30]. All analyses were performed using Stata v16.0 (Stata Corp, College

Station, TX) and R v3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Sample characteristics

Table 1 shows the characteristics of participants in the full sample and COVID-19 positive

sample. In the full sample of 437,555 participants, the mean age as of the year 2020 was 68.1

(standard deviation [SD] 8.1) and 55.3% were women. The proportions of men, Black ethnicity,

previous or current smokers, low education, lowest income and most deprived groups were

higher in the COVID-19 positive sample than the full sample. Frailty appeared to be over-

represented among COVID-19 positive individuals, with 21.6% being "frail" (assessed by FI)

and 22.4% being "high frailty risk" (assessed by HFRS), compared to 12.1% and 2.9% in the full

sample. Logistic regression models for COVID-19 positivity showed that FI, HFRS, and CCI were

all associated with higher risk of being COVID-19 positive, after adjusting for age and sex

(*Appendix* **Table S6**).

Frailty and comorbidity in predicting COVID-19 mortality

In total, 408 individuals died of COVID-19 between 1st March and 24th August 2020. Results for

the logistic regression models for COVID-19 mortality are presented in **Table 2**. In the full

sample, when each of the measures – FI, HFRS, and CCI were tested separately, they were

significantly associated with higher odds of COVID-19 mortality after controlling for age and

sex (models 2–4). AUROC for the model including only age and sex was 0.76 (95% confidence

interval [CI] 0.74–0.78); adding FI into the model resulted in a slightly larger AUROC of 0.78

(95% CI 0.76–0.80), while adding HFRS and CCI yielded significantly larger AUROCs of 0.83

(95% CI 0.81–0.86) and 0.82 (95% CI 0.80–0.84) respectively (**Fig. 2A**). In the multivariable

model with both frailty measures and the CCI included (model 5), HFRS (odds ratio [OR] 1.07;

95% CI 1.06–1.07) and CCI (OR 1.14; 95% CI 1.08–1.20), but not FI, predicted statistically

significantly higher risk of COVID-19 mortality. AUROC of the multivariable model (0.84; 95%

CI 0.83–0.87) was similar to the age and sex-adjusted univariable models of HFRS and CCI (**Fig.**

2A). After restricting the sample to COVID-19 positive individuals, all of these associations

were attenuated, and the predictive accuracies were decreased. In the fully adjusted model

(model 5), only CCI was marginally associated with COVID-19 mortality (OR 1.09; 95% CI 1.01–

1.14). Frailty and comorbidity did not add predictive value on top of age and sex, as indicated

by similar AUROCs across all models (**Fig. 2B**). We subsequently adjusted for ethnicity, smoking

and socioeconomic variables in both samples; associations of frailty and comorbidity with

COVID-19 mortality were not affected by these variables (***Appendix* Table S7**).

In both samples, compared with older individuals (≥75 years), relatively younger

individuals (<75 years) had higher ORs for COVID-19 mortality across HFRS categories (**Fig. 3**);

there was also significant interaction between HFRS and age in the COVID-19 positive sample

($P_{interaction}$<0.001), but not in the full sample (***Appendix* Table S8**). We also tested the

interaction between HFRS and sex, yet it was not statistically significant and thus we did not

further perform subgroup analysis by sex.

Sensitivity analyses

The predictive abilities of frailty and comorbidity for COVID-19 mortality were largely similar

compared to the main analyses when (i) using FI and HFRS as categorical instead of continuous

variables (***Appendix* Table S9**), (ii) using the 2-year HFRS and CCI variables instead of the

original scores (*Appendix* **Table S10**), and (iii) accounting for competing risk by deaths due to

other causes than COVID-19 (*Appendix* **Table S11**).

Discussion

Using data from the UK Biobank, we found that HFRS and CCI, measures of frailty and

comorbidity respectively, were viable predictors of COVID-19 mortality and added predictive

value on top of age and sex in the overall community population. The associations persisted

even after adjusting for ethnicity, smoking and socioeconomic variables. Nonetheless, among

COVID-19 positive individuals who were already more likely to be frail, HFRS and CCI did not

improve predictive accuracy for COVID-19 mortality in addition to age and sex. Stronger

associations between HFRS and COVID-19 mortality were seen among younger (<75 years)

than older individuals (≥75 years), indicating that the HFRS may be applicable for predicting

mortality risk in younger adults as well.

To the best of our knowledge, this is the first study that has assessed the associations

between frailty and COVID-19 mortality in the community population. We showed that frailty

was associated with an elevated risk of COVID-19 mortality, and that a HFRS constructed

based on ICD-10 codes was a stronger predictor than an FI calculated using self-reported data

at baseline. The CCI, a measure of comorbidity computed by ICD-10 codes, likewise predicted

COVID-19 mortality, which is in line with prior research showing a positive association

between comorbidity and COVID-19 deaths [18,21,31]. Together, our results imply that frailty

and comorbidity measures available in routinely collected medical records may be applied for

risk stratification of COVID-19 mortality in the overall community population.

However, the predictive accuracies of frailty and comorbidity for COVID-19 mortality

were reduced after restricting the sample to only those with the disease. It has been argued

that using non-random samples may induce selection bias in COVID-19-related studies [24]. In our COVID-19 positive sample, there was an over-representation of the most frail individuals, with even greater proportion of the "high frailty risk" group in our sample than in the cohort of older hospitalized individuals in the original HFRS study (22.1% vs 20.0%) [13]. Consistent with a previous study [32], we confirmed that frailty and comorbidities are determinants of being COVID-19 positive in the UK Biobank sample. Such over-representation of frailty may partly explain the inconsistencies in the frailty-mortality associations among hospitalized COVID-19 patients [16–22]. In a relatively frail sample, COVID-19 mortality risk may in fact be more related to other factors, such as viral load and host immune characteristics [20,33]. Indeed, none of our models in the COVID-19 positive sample yielded a good predictive accuracy of AUROC>0.8, even when smoking, ethnicity and socioeconomic variables were included. More research is warranted to identify the most accurate predictors for mortality among COVID-19 patients.

Given that the HFRS was initially developed for older individuals, we stratified the analysis by age and observed a more pronounced association between HFRS and COVID-19 mortality among the younger individuals (<75 years). A similar pattern has also been reported in the literature, in which frailty has shown to be more strongly associated with mortality at younger old ages than the oldest ages [9,25]. Our findings thus highlight the importance of frailty screening in younger individuals in prevention for COVID-19 related mortality.

The large sample of UK Biobank participants with linkage to COVID-19 data enabled us to study the associations among the overall population and to examine the potential effects of sample selection. Nevertheless, there are several caveats to this study. Firstly, demographic variables, socio-economic indicators and the deficits for construction of FI were assessed during baseline in 2006–2010. In particular, the FI, calculated by self-reported data ~10 years

ago, may not fully reflect participants' current physiological status. Future research may utilize

an FI based on routine primary care data, such as the electronic FI [34], for assessing its

predictive ability for COVID-19 mortality among the general population. Secondly, with the

limitation of data availability, we were not able to retrieve test results and hospital inpatient

data for people living in Scotland or Wales. Thirdly, during the earlier periods of the epidemic,

COVID-19 testing in the UK was largely restricted to hospitalized individuals, who have more

severe course of the diseases. As such, mild or asymptomatic COVID-19 cases may conceivably

be missed, leading to an underestimation of COVID-19 positive cases. Fourthly, we modelled

the outcome, COVID-19 mortality, as a binary variable rather than a time-to-event or survival

outcome because we could not ascertain the exact date of confirmed COVID-19 infection for

several individuals in the COVID-19 positive subsample. However, as the follow-up time was

limited, it could be considered essentially complete for most participants (i.e., minimal

censoring due to migration and other deaths). Finally, UK Biobank is not a nationally

representative sample, with generally healthier and less socioeconomically deprived

participants than the UK average [35], thereby reducing the generalizability of our findings.

Conclusions and implications

In conclusion, HFRS and CCI, measures of frailty and comorbidity respectively, constructed

using routinely collected medical records, predicted COVID-19 mortality in the overall

community sample and added predictive value on top age and sex. However, similar effects

were not seen in those who already have the disease. Our findings suggest that identification

of frail individuals in the general population may be a viable strategy for COVID-19 mortality

risk stratification.

Acknowledgements

This research was conducted using the UK Biobank resource, as part of the registered project 22224.

Declarations

Funding: This work was supported by the Swedish Research Council (2018-02077, 2019-01272), the Loo & Hans Osterman Foundation, the Strategic Research Program in Epidemiology at Karolinska Institutet and the Karolinska Institutet Foundations.

Conflicts of interest: The authors declare that they have no conflict of interest.

Ethical approval: Ethical approval for this study is covered by the general ethics review for the UK Biobank, conducted by North West Multi-Centre Research Ethics Committee (Reference: 16/NW/0274, 13 May 2016).

Consent to participate: Informed consent was obtained from all individual participants included in the study.

Consent to publish: Not applicable.

Availability of data and material: UK Biobank is an open access resource. All bona fide researchers can apply to use its data for health-related research that is in the public interest (http://www.ukbiobank.ac.uk/register-apply).

Code availability: Not applicable.

Authors' contributions: J.K.L.M., R.K.-H., and J.J. contributed to the study concept and design; Y.W., S.H. and J.J. were responsible for acquisition of data; J.K.L.M., R.K.-H. and J.J. analysed and interpreted the data; J.K.L.M. and J.J. drafted the manuscript; R.K.-H., Y.W. and S.H. critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real

time. Lancet Infect Dis. 2020;20:533–4.

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of

adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.

2020;395:1054–62.

3. O'Dowd A. Covid-19: People in most deprived areas of England and Wales twice as likely to

die. BMJ. 2020;369:m2389.

4. Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19

patients. Diabetes Res Clin Pract. 2020;166:108293.

5. Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk

factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis: Mortality-

related risk factors of COVID-19, SARS, and MERS. J. Infect. 2020. p. e18.

6. Golestaneh L, Neugarten J, Fisher M, Billett HH, Gil MR, Johns T, et al. The association of

race and COVID-19 mortality. EClinicalMedicine. 2020;25.

7. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet.

2013;381:752–62.

8. Grabovac I, Haider S, Mogg C, Majewska B, Drgac D, Oberndorfer M, et al. Frailty Status

Predicts All-Cause and Cause-Specific Mortality in Community Dwelling Older Adults. J Am

Med Dir Assoc. 2019;20:1230-1235.e2.

9. Li X, Ploner A, Karlsson IK, Liu X, Magnusson PKE, Pedersen NL, et al. The frailty index is a

predictor of cause-specific mortality independent of familial effects from midlife onwards: A

large cohort study. BMC Med. 2019;17:94.

10. Williams DM, Jylhävä J, Pedersen NL, Hägg S. A Frailty Index for UK Biobank Participants.

Journals Gerontol - Ser A Biol Sci Med Sci. 2019;74:582–7.

11. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global

clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.

12. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for

creating a frailty index. BMC Geriatr. 2008;8:24.

13. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, et al. Development and

validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using

electronic hospital records: an observational study. Lancet. 2018;391:1775–82.

14. Kundi H, Wadhera RK, Strom JB, Valsdottir LR, Shen C, Kazi DS, et al. Association of Frailty

with 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia among

Elderly Adults. JAMA Cardiol. 2019;4:1084–91.

15. McAlister F, Van Walraven C. External validation of the Hospital Frailty Risk Score and

comparison with the Hospital-patient One-year Mortality Risk Score to predict outcomes in

elderly hospitalised patients: A retrospective cohort study. BMJ Qual Saf. 2019;28:284–8.

16. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of

frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational

cohort study. Lancet Public Heal. 2020;5:e444–51.

17. Aw D, Woodrow L, Ogliari G, Harwood R. Association of Frailty with Mortality in Older

Inpatients with Covid-19: A Cohort Study. Age Ageing. 2020;1–8.

18. Hägg S, Jylhävä J, Wang Y, Xu H, Metzner C, Annetorp M, et al. Age, frailty and comorbidity

as prognostic factors for short-term outcomes in patients with COVID-19 in geriatric care. J

Am Med Dir Assoc. 2020;0.

19. Kundi H, Çetin EHÖ, Canpolat U, Aras S, Celik O, Ata N, et al. The role of Frailty on Adverse

Outcomes Among Older Patients with COVID-19. J Infect. 2020;

20. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, et al. Frailty and

Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. J

Am Med Dir Assoc. 2020;21:928-932.e1.

21. Owen RK, Conroy SP, Taub N, Jones W, Bryden D, Pareek M, et al. Comparing associations

between frailty and mortality in hospitalised older adults with or without COVID-19 infection:

a retrospective observational study using electronic health records. Age Ageing. 2020;1.

22. Miles A, Webb TE, Mcloughlin BC, Mannan I, Rather A, Knopp P, et al. Outcomes from

COVID-19 across the range of frailty: excess mortality in fitter older people. Eur Geriatr Med.

2020;1:3.

23. Collins JT, Short R, Carter B, Verduri A, Myint PK, Quinn TJ, et al. The Clinical Frailty Scale:

Estimating the Prevalence of Frailty in Older Patients Hospitalised with COVID-19. The COPE

Study. Geriatr (Basel, Switzerland). 2020;5.

24. Griffith G, Morris TT, Tudball M, Herbert A, Mancano G, Pike L, et al. Collider bias

undermines our understanding of COVID-19 disease risk and severity. medRxiv.

2020;2020.05.04.20090506. Available from: https://doi.org/10.1101/2020.05.04.20090506

25. Tran DTT, Tu J V., Dupuis JY, Eddeen AB, Sun LY. Association of frailty and long-term survival

in patients undergoing coronary artery bypass grafting. J Am Heart Assoc. 2018;7.

26. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open

Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle

and Old Age. 2015;12:e1001779.

27. Armstrong J, Rudkin JK, Allen N, Crook DW, Wilson DJ, Wyllie DH, et al. Dynamic linkage of

covid-19 test results between public health england's second generation surveillance system

and uk biobank. Microb Genomics. 2020;6:1–9.

28. Rockwood K, Song X, Mitnitski A. Changes in relative fitness and frailty across the adult

lifespan: Evidence from the Canadian National Population Health Survey. CMAJ.

2011;183:E487-94.

29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic

comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–

83.

30. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful

Approach to Multiple Testing. J R Stat Soc Ser B. 1995;57:289–300.

31. Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo C-L, Kuchel GA, et al. Preexisting

Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort.

Journals Gerontol Ser A. 2020;75:2224–30.

32. Woolford SJ, D'Angelo S, Curtis EM, Parsons CM, Ward KA, Dennison EM, et al. COVID-19

and associations with frailty and multimorbidity: a prospective analysis of UK Biobank

participants. Aging Clin Exp Res. 2020;32:1897–905.

33. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients

With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020;71:1393–9.

34. Clegg A, Bates C, Young J, Ryan R, Nichols L, Ann Teale E, et al. Development and validation

of an electronic frailty index using routine primary care electronic health record data. Age

Ageing. 2016;45:353–60.

35. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of

Sociodemographic and Health-Related Characteristics of UK Biobank Participants with Those

of the General Population. Am J Epidemiol. 2017;186:1026–34.

Tables and Figures

Table 1 Characteristics of UK Biobank participants in the full sample and COVID-19 positive sample

	Full sample (*n*=437,555)	COVID-19 positive sample (*n*=2,059)
Deaths, n (%)	2,146 (0.5)	477 (23.2)
Age (years), mean ± SD	68.1 ± 8.1	68.8 ± 9.0
Sex, n (%)		
Women	241,791 (55.3)	976 (47.4)
Men	195,764 (44.7)	1,083 (52.6)
Ethnicity, n (%)		
White	411,094 (94.3)	1,798 (87.7)
Asian	10,471 (2.4)	94 (4.6)
Black	7,608 (1.7)	102 (5.0)
Others	6,886 (1.6)	57 (2.8)
Smoking status, n (%)		
Never	242,414 (55.6)	981 (48.0)
Previous	150,245 (34.5)	806 (39.5)
Current	43,346 (9.9)	256 (12.5)
Education, n (%)		
Low	70,461 (16.4)	512 (25.6)
Intermediate	218,540 (50.9)	999 (50.0)
High	140,713 (32.8)	489 (24.5)
Income, n (%)		
<£18,000	81,674 (22.0)	564 (33.5)
£18,000–30,999	94,319 (25.4)	438 (26.0)
£31,000–51,999	98,079 (26.4)	372 (22.1)
≥£52,000	97,456 (26.3)	311 (18.5)
Townsend deprivation quintile, n (%)		
1 (least deprived)	87,712 (20.1)	291 (14.1)
2	88,844 (20.3)	334 (16.2)
3	88,525 (20.3)	375 (18.2)
4	87,596 (20.0)	431 (20.9)
5 (most deprived)	84,352 (19.3)	627 (30.5)
Frailty Index, median (IQR)	0.112 (0.066–0.163)	0.133 (0.083–0.199)
By category, n (%):		
Relatively fit (≤0.03)	26,412 (6.0)	78 (3.8)
Less fit (>0.03–0.1)	164,761 (37.7)	604 (29.3)
Least fit (>0.1–0.21)	193,409 (44.2)	933 (45.3)
Frail (>0.21)	52,973 (12.1)	444 (21.6)
Hospital Frailty Risk Score, median (IQR)	0.7 (0–3.2)	3.2 (0–12.9)
By category, n (%):		
Low risk (<5)	365,958 (83.6)	1,196 (58.1)
Intermediate risk (5–15)	59,046 (13.5)	402 (19.5)
High risk (>15)	12,551 (2.9)	461 (22.4)
Charlson Comorbidity Index, median (IQR)	0 (0–1)	1 (0–3)

IQR, interquartile range; SD, standard deviation

Table 2 Logistic regression models for the associations of age, sex, frailty and comorbidity with COVID-19 mortality in the full sample and COVID-19 positive sample

	Model 1: age + sex	Model 2: FI + age + sex	Model 3: HFRS + age + sex	Model 4: CCI + age + sex	Model 5: Multivariable
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
(a) Full sample (*n*=437,555)					
Age	1.14 (1.12–1.16)*	1.13 (1.11–1.15)*	1.11 (1.09–1.13)*	1.11 (1.09–1.13)*	1.10 (1.09–1.12)*
Male sex	1.99 (1.63–2.44)*	2.12 (1.73–2.59)*	1.93 (1.57–2.36)*	1.77 (1.45–2.17)*	1.86 (1.52–2.29)*
FI (per 10% increase)		1.70 (1.52–1.90)*			1.09 (0.96–1.23)
HFRS			1.08 (1.07–1.09)*		1.07 (1.06–1.07)*
CCI				1.40 (1.35–1.45)*	1.14 (1.08–1.20)*
Area under the ROC curve	0.76 (0.74–0.78)	0.78 (0.76–0.80)	0.83 (0.81–0.86)	0.82 (0.80–0.84)	0.84 (0.83–0.87)
(b) COVID-19 positive sample (*n*=2,059)					
Age	1.12 (1.10–1.14)*	1.12 (1.10–1.14)*	1.11 (1.09–1.13)*	1.11 (1.10–1.13)*	1.11 (1.09–1.13)*
Male sex	1.45 (1.14–1.83)*	1.47 (1.16–1.87)*	1.44 (1.14–1.83)*	1.43 (1.13–1.81)*	1.43 (1.12–1.81)*
FI (per 10% increase)		1.09 (0.96–1.25)			1.00 (0.87–1.15)
HFRS			1.01 (1.00–1.02)*		1.01 (1.00–1.01)
CCI				1.09 (1.04–1.15)*	1.09 (1.01–1.14)*
Area under the ROC curve	0.74 (0.72–0.77)	0.74 (0.72–0.77)	0.75 (0.72–0.77)	0.75 (0.72–0.77)	0.75 (0.72–0.77)

CCI, Charlson comorbidity index; CI, confidence interval; FI, Frailty Index; HFRS, Hospital Frailty Risk Score; OR, odds ratio; ROC, receiver operating characteristic curve.

*Significant with a false discovery rate corrected significance level at 0.044

Fig. 1 Flowchart of selection of study sample from the UK Biobank

Fig. 2 Receiver operating characteristic (ROC) curves for age, sex, frailty and comorbidity in predicting COVID-19 mortality. **(A)** Analyses performed in the full UK Biobank sample (*n*=437,555); **(B)** analyses performed in the COVID-19 positive sample (*n*=2,059). Model 1 to model 4 are univariable logistic regression models adjusted for age and sex, while model 5 is the multivariable logistic regression model. AUC, area under the receiver operating characteristic curves; CCI, Charlson comorbidity index; FI, Frailty Index; HFRS, Hospital Frailty Risk Score

Fig. 3 Associations between Hospital Frailty Risk Score and COVID-19 mortality stratified by age into younger (<75 years) and older (≥75 years) individuals in full sample (*n*=437,555) and in COVID-19 positive sample (*n*=2,059). Error bars indicate 95% confidence intervals. Models were adjusted for sex.

Note: The point estimates for the stratified analysis can be found in *Appendix* Table S8